Immuron Ltd (IMRN) Form 6-K — Oct 13, 2026
Immuron announced that Phase 2 data for once-daily oral Travelan was published in Nature journal Scientific Reports on October 13, 2026. The DoD-funded study showed Travelan was safe and well tolerated, with a statistically significant 50% reduction in ETEC challenge-related adverse events versus placebo (P=0.0001), plus 40-50% reductions in moderate-to-severe and severe diarrhoea. However, the study missed its primary efficacy endpoints because the placebo attack rate came in at 33% versus the anticipated 70%, materially reducing statistical power, though efficacy trends favored Travelan across multiple endpoints.
Key figures
- Placebo attack rate
- 33% vs 70% anticipated
- Seroconversion rate
- >80% by day 15-29
- Prior protection rates
- 58.3% (p=0.02), 76.7% (p=0.007), 90.9% (p=0.0005)
- Adverse event reduction
- 50% (P=0.0001)
- All diarrhoea reduction
- 44%
- Severe diarrhoea reduction
- 50%
- Early antibiotic use reduction
- 71%
- Moderate to severe diarrhoea reduction
- 40%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.